Regeneron makes Eylea (eye disease) and co-owns Dupixent (eczema/asthma), two of medicine's biggest sellers.
Regeneron Pharmaceuticals, Inc. (REGN) is expected to report earnings on Friday, October 30, 2026, before the open. Estimated release time 06:51 ET. Consensus EPS estimate is $16.07.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-07-30 | Jun 2026 qtr | $10.16 | $14.29 | — | $4.29B |
| 2026-04-29 | Mar 2026 qtr | $8.91 | $9.47 | +6.3% | $3.61B |
| 2026-01-30 | Dec 2025 qtr | $10.74 | $11.44 | +6.5% | $3.88B |
| 2025-10-28 | Sep 2025 qtr | $9.65 | $11.83 | — | $3.75B |
| 2025-08-01 | Jun 2025 qtr | $8.43 | $12.89 | — | $3.68B |
| 2025-04-29 | Mar 2025 qtr | $8.62 | $8.22 | -4.6% | $3.03B |
| 2025-02-04 | Dec 2024 qtr | $11.21 | $12.07 | +7.7% | $3.79B |
| 2024-10-31 | Sep 2024 qtr | $11.69 | $12.46 | +6.6% | $3.72B |
REGN has beaten consensus EPS in 4 of its last 5 scored quarters.
REGN pays a quarterly dividend, currently yielding 0.46%.
| Ex-dividend date | Amount | Paid |
|---|---|---|
| 2026-08-18 | $0.94 | 2026-08-31 |
| 2026-05-20 | $0.94 | 2026-06-04 |
| 2026-02-20 | $0.94 | 2026-03-05 |
| 2025-11-20 | $0.88 | 2025-12-05 |
| 2025-08-18 | $0.88 | 2025-09-03 |
| 2025-05-20 | $0.88 | 2025-06-06 |